Trade-Ideas LLC identified

Edwards Lifesciences

(

EW

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Edwards Lifesciences as such a stock due to the following factors:

  • EW has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $151.1 million.
  • EW has traded 224,346 shares today.
  • EW is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in EW with the Ticky from Trade-Ideas. See the FREE profile for EW NOW at Trade-Ideas

More details on EW:

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. EW has a PE ratio of 45. Currently there are 11 analysts that rate Edwards Lifesciences a buy, no analysts rate it a sell, and 5 rate it a hold.

The average volume for Edwards Lifesciences has been 1.7 million shares per day over the past 30 days. Edwards Lifesciences has a market cap of $22.5 billion and is part of the health care sector and health services industry. The stock has a beta of 0.57 and a short float of 1.7% with 2.77 days to cover. Shares are up 34.9% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Edwards Lifesciences as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

Highlights from the ratings report include:

  • The revenue growth came in higher than the industry average of 5.7%. Since the same quarter one year prior, revenues rose by 18.1%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • EW's debt-to-equity ratio is very low at 0.26 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Along with this, the company maintains a quick ratio of 2.92, which clearly demonstrates the ability to cover short-term cash needs.
  • Investors have apparently begun to recognize positive factors similar to those we have mentioned in this report, including earnings growth. This has helped drive up the company's shares by a sharp 36.17% over the past year, a rise that has exceeded that of the S&P 500 Index. Regarding the stock's future course, although almost any stock can fall in a broad market decline, EW should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
  • Net operating cash flow has increased to $107.10 million or 46.11% when compared to the same quarter last year. In addition, EDWARDS LIFESCIENCES CORP has also vastly surpassed the industry average cash flow growth rate of -17.43%.
  • EDWARDS LIFESCIENCES CORP has improved earnings per share by 17.9% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, EDWARDS LIFESCIENCES CORP reported lower earnings of $2.25 versus $3.76 in the prior year. This year, the market expects an improvement in earnings ($2.75 versus $2.25).

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.